Lupin gets USFDA nod for cholesterol drug

New Delhi: Drug major Lupin on Thursday said it has received approval from the US health regulator to market generic fenofibrate tablets, used to treat high cholesterol, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to market generic version of Teva’s Fenofibrate tablets in strengths of 54mg and 160mg, Lupin said in a statement.

The Mumbai-based company’s US unit, Lupin Pharmaceuticals Inc would commence promoting the product shortly in the US, it added.

According to IMS MAT June data, fenofibrate tablets in strengths of 54 mg and 160 mg had US sales of $156 million.

Lupin has close to 20% market share of the overall US Fenofibrate market. The drug firm now has a total of 81 products in the US market.

Lupin shares on Thursday ended at Rs 1,892.10 apiece on BSE, up 5.39% from its previous close.